RxDoctor Payments Data

Brittany Adams

Family · Oak Ridge, TNNPI 1295261220

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.1% of the total across 752 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $5,653 and has fallen 77.6% since, to $1,266 in 2025. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,839in general payments, 2019–2025

Across 752 payments — averaging $25.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$2K
  • Novartis$2K
  • Johnson & Johnson$2K
  • Seagen Inc.$2K
  • Bristol Myers Squibb$1K
  • AstraZeneca$1K
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$17,15891%
  • Education$1,0005%
  • Other$6824%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.88$2,396
Novartis62$1,789
Johnson & Johnson(2 entities)45$1,628
Seagen Inc.62$1,567
Bristol Myers Squibb62$1,133
AstraZeneca(2 entities)39$1,062
Incyte Corporation33$950
Merck27$588
Pfizer31$519
Genentech USA, Inc.28$505
Astellas Pharma US Inc19$473
AbbVie19$465
Daiichi Sankyo Inc.24$464
Takeda Pharmaceuticals U.S.A., Inc.11$420
GSK11$354
Amgen18$317
Eisai Inc.11$275
Gilead(2 entities)9$262
Beigene USA, Inc.5$237
Lilly USA, LLC11$221
Kyowa Kirin, Inc.9$206
Regeneron Healthcare Solutions, Inc.7$206
Puma Biotechnology, Inc.7$183
Sanofi9$169
Exelixis Inc.3$154
Rigel Pharmaceuticals, Inc.10$140
Mirati Therapeutics, Inc.5$128
Coherus Oncology, Inc.1$125
Array Biopharma Inc8$123
AMAG Pharmaceuticals, Inc.1$122
Deciphera Pharmaceuticals Inc.5$118
Bayer6$112
AVEO Pharmaceuticals, Inc.2$99
Jazz Pharmaceuticals Inc.2$98
Caris MPI, Inc.1$90
Pharmacyclics LLC, An Abbvie Company5$83
Morphosys, US Inc.5$80
Boston Scientific4$79
Pharmacosmos Therapeutics Inc.4$67
Tersera Therapeutics LLC3$62
Karyopharm Therapeutics Inc.3$62
Ipsen Biopharmaceuticals, Inc4$60
Springworks Therapeutics, Inc.2$57
Pharmaessentia USA Corporation3$56
Taiho Oncology, Inc.3$51
Ferring Pharmaceuticals Inc.2$45
Epizyme, Inc.2$40
Genmab U.S., Inc.2$38
Acceleron Pharma, Inc.2$38
Acrotech Biopharma Inc.2$37
Sun Pharmaceutical Industries Inc.1$36
Sobi, Inc2$34
EMD Serono, Inc.2$34
Blueprint Medicines Corporation2$34
Tempus AI, Inc1$31
Agios Pharmaceuticals, Inc.1$19
Boehringer Ingelheim1$18
Beone Medicines USA, Inc.1$16
ADC Therapeutics America, Inc.1$16
Novo Nordisk1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,839 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$19,244
Medicare patients
105
Services billed
216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide23$312,648
TagrissoOsimertinib Mesylate14$223,262
Lenalidomide19$209,560
VenclextaVenetoclax11$154,038
PromactaEltrombopag Olamine12$108,042
EliquisApixaban26$24,825
Anastrozole50$3,078
Morphine Sulfate ErMorphine Sulfate26$647
Oxycodone Hcl21$427
Gabapentin28$245
Potassium Chloride15$222
Lidocaine-PrilocaineLidocaine/Prilocaine12$118
Levothyroxine Sodium11$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$473$312,64823 claims
AstraZenecaTagrisso$1,062$223,26214 claims
AbbVieVenclexta$465$154,03811 claims
NovartisPromacta$1,789$108,04212 claims
PfizerEliquis$519$24,82526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Oak Ridge

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →